Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00013585 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: May 21, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cognition Disorders HIV Infections | Drug: Selegiline hydrochloride | Phase 2 |
Cognitive impairment is a common adverse effect of HIV infection that can progress to dementia. ARVs are the only current therapy, but treatment response is frequently unsatisfactory, short lived, or the agents are poorly tolerated in doses adequate for central nervous system (CNS) penetration. An adjunctive therapy that interferes with the cascade of events triggered by the virus is likely to play an important role. Oral selegiline is an approved and marketed drug for the symptomatic treatment of Parkinson's disease. Studies suggest that selegiline has a neuroprotective effect and that it may exert a "rescue effect" on dying and injured neurons. This study proposes to use transdermal selegiline, which may deliver a greater dose level than oral administration, in the treatment of HIV-associated cognitive impairment.
This is a two-step study, with each step lasting 24 weeks. Step 1 is double-blind and Step 2 is open label. At entry, patients are randomly assigned to receive either the STS or placebo. One STS patch will be applied daily at the same time for 24 weeks. Patients are evaluated at the clinic at entry and at Weeks 2, 4, 8, 12, 16, and 24. Cognitive status will be evaluated by performance on a series of neuropsychological assessments. Patients who complete Step 1 may participate in Step 2. Patients on placebo in Step 1 will receive active STS treatment in Step 2. The STS patch is applied once daily for an additional 24 weeks and patients are evaluated at the clinic at Weeks 28, 36, and 48.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 127 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Phase II, Placebo-Controlled, Double-Blind Study of the Selegiline Transdermal System (STS) in the Treatment of HIV-Associated Cognitive Impairment |
Actual Study Completion Date : | December 2005 |

- Change in cognitive performance Week 24 from screening
- frequencies of adverse experiences, abnormal results on laboratory tests, changes over time in laboratory tests and vital signs
- Clinical global impression by the investigator comparing selegiline-treated arms with the placebo arm
- clinical global impression by the subject comparing selegiline-treated arms with the placebo arm
- cognitive domain-specific scores compared between selegiline-treated arms and the placebo arm
- neuropsychologic function tests (NPZ-8)
- fatigue scale (quality of life)
- markers of immune activation and oxidative stress/apoptosis
- comparison of selegiline and active metabolite steady-state concentrations at Weeks 4, 12, and 24 to cognitive performance
- comparison of selegiline and active metabolite steady-state concentrations at Weeks 4, 12, and 24 to historical data in normal volunteers after 7 days of transdermal selegiline administration
- comparison of selegiline and active metabolite steady-state concentrations at Week 4 in subjects on ritonavir-containing protease inhibitor (PI) antiviral regimens, subjects on other PI regimens, and subjects on non-PI-containing antiviral regimens

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Note: This trial closed to accrual on 12/15/04. Use of the lower-dose STS was discontinued on 05/31/05. Any patients joining the study after 05/31/05 assigned to the interventional arm or who are currently enrolled in Step 2 will receive the higher-dose STS.
Inclusion Criteria:
- HIV infected
- Stable anti-HIV therapy or no anti-HIV therapy for at least 8 weeks prior to study screening
- AIDS Dementia Complex Stage of greater than 0
- Decreased mental function as shown by tests during screening
- IQ of 70 or greater
- Willing to use acceptable methods of contraception during study and for 3 months following study
Exclusion Criteria:
- Tumor involving a large organ or requiring chemotherapy. Patients with basal cell carcinoma, in situ carcinoma of the cervix, or Kaposi's sarcoma are not excluded.
- Serious mental illness that, in the opinion of the investigator, might interfere with the study
- Reserpine or meperidine within 7 days prior to study entry
- Nefazodone within 14 days prior to study entry
- Monoamine oxidase inhibitor, including selegiline, within 30 days prior to study entry
- Sympathomimetic medications, including over the counter diet and cold (oral or nasal) remedies, within 14 days of study entry
- Decreased blood pressure when standing up
- Uncontrolled high blood pressure
- Active symptomatic AIDS-defining opportunistic infection within 30 days prior to study entry
- Nervous system disorders such as multiple sclerosis, stroke, serious head injury, uncontrolled epilepsy, Tourette's syndrome, Huntington's disease, dementias due to alcohol abuse, vitamin B12 deficiency, or syphilis
- CNS infections or neoplasms including cytomegalovirus (CMV) encephalitis, toxoplasmosis, primary or metastatic CNS lymphoma, progressive multifocal leukoencephalopathy, cryptococcal or other fungal meningitis, tuberculous CNS infection, or untreated neurosyphilis
- Any other condition that, in the investigator's opinion, would interfere with the study
- Certain investigational drugs within 30 days before study entry
- Allergic to selegiline or the STS patch
- Pregnant or breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00013585
United States, California | |
UCLA CARE Center CRS | |
Los Angeles, California, United States, 90095 | |
Ucsd, Avrc Crs | |
San Diego, California, United States, 92103 | |
United States, Hawaii | |
Univ. of Hawaii at Manoa, Leahi Hosp. | |
Honolulu, Hawaii, United States, 96816 | |
United States, Illinois | |
Northwestern University CRS | |
Chicago, Illinois, United States, 60611 | |
Cook County Hosp. CORE Ctr. | |
Chicago, Illinois, United States, 60612 | |
United States, Maryland | |
Johns Hopkins Adult AIDS CRS | |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Massachusetts General Hospital ACTG CRS | |
Boston, Massachusetts, United States, 02114 | |
United States, Missouri | |
Washington U CRS | |
St. Louis, Missouri, United States | |
United States, New York | |
Beth Israel Med. Ctr., ACTU | |
New York, New York, United States, 10003 | |
Columbia Univ., HIV Prevention and Treatment Medical Ctr. | |
New York, New York, United States, 10032 | |
Univ. of Rochester ACTG CRS | |
Rochester, New York, United States, 14642 | |
United States, North Carolina | |
Unc Aids Crs | |
Chapel Hill, North Carolina, United States, 27514 | |
United States, Pennsylvania | |
Hosp. of the Univ. of Pennsylvania CRS | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Rhode Island | |
The Miriam Hosp. ACTG CRS | |
Providence, Rhode Island, United States, 02906 | |
United States, Washington | |
University of Washington AIDS CRS | |
Seattle, Washington, United States, 98104 |
Study Chair: | Giovanni Schifitto, M.D. | Department of Neurology, University of Rochester Medical Center | |
Study Chair: | Ned Sacktor, M.D. | Department of Neurology, Johns Hopkins University Bayview Medical Center | |
Study Chair: | David Simpson, M.D. | Department of Clinical Neurophysiology, Mount Sinai School of Medicine |
Publications of Results:
Other Publications:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00013585 History of Changes |
Other Study ID Numbers: |
A5090 10075 ( Registry Identifier: DAIDS ES ) ACTG A5090 AACTG A5090 |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | May 21, 2012 |
Last Verified: | May 2012 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Cognitive Disorders AIDS Dementia Complex Selegiline Administration, Cutaneous Neuroprotective Agents |
Additional relevant MeSH terms:
HIV Infections Cognition Disorders Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Neurocognitive Disorders |
Mental Disorders Selegiline Antiparkinson Agents Anti-Dyskinesia Agents Monoamine Oxidase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Neuroprotective Agents Protective Agents Physiological Effects of Drugs |